OBJECTIVE: Vancomycin resistant enterococcal (VRE) blood stream infection (BSI) in neutropenic patients is associated with poor outcome. We report our experience in treating VRE BSI in febrile, neutropenic patients with daptomycin, a recently licensed lipopeptide with bactericidal activity against VRE. PATIENTS AND METHODS: Patients with fever, neutropenia and VRE BSI were treated with more than one dose of daptomycin (either 6 mg/kg/day or 4 mg/kg/day) in an open label, emergency-use trial. Patients were then assessed for clinical and microbiological cures and survival. MIC's of isolates to daptomycin were determined. RESULTS: Nine febrile, neutropenic patients with VRE BSI received daptomycin. Four of 9 courses (44%) had clinical and/or microbiologic cure. Two of the 5 who failed cure died within 3 days of initiation of daptomycin. Five subjects survived to 30 days after the onset of BSI. CONCLUSIONS: Use of daptomycin in neutropenic patients with VRE BSI deserves further study as a treatment for VRE BSI in neutropenic patients.
OBJECTIVE:Vancomycin resistant enterococcal (VRE) blood stream infection (BSI) in neutropenicpatients is associated with poor outcome. We report our experience in treating VRE BSI in febrile, neutropenicpatients with daptomycin, a recently licensed lipopeptide with bactericidal activity against VRE. PATIENTS AND METHODS: Patients with fever, neutropenia and VRE BSI were treated with more than one dose of daptomycin (either 6 mg/kg/day or 4 mg/kg/day) in an open label, emergency-use trial. Patients were then assessed for clinical and microbiological cures and survival. MIC's of isolates to daptomycin were determined. RESULTS: Nine febrile, neutropenicpatients with VRE BSI received daptomycin. Four of 9 courses (44%) had clinical and/or microbiologic cure. Two of the 5 who failed cure died within 3 days of initiation of daptomycin. Five subjects survived to 30 days after the onset of BSI. CONCLUSIONS: Use of daptomycin in neutropenicpatients with VRE BSI deserves further study as a treatment for VRE BSI in neutropenicpatients.
Authors: James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191
Authors: J A DesJardin; M E Falagas; R Ruthazer; J Griffith; D Wawrose; D Schenkein; K Miller; D R Snydman Journal: Ann Intern Med Date: 1999-11-02 Impact factor: 25.391
Authors: Jennifer K Long; Toni K Choueiri; Geraldine S Hall; Robin K Avery; Mikkael A Sekeres Journal: Mayo Clin Proc Date: 2005-09 Impact factor: 7.616
Authors: D Kapur; D Dorsky; J M Feingold; R D Bona; R L Edwards; J Aslanzadeh; P J Tutschka; S Bilgrami Journal: Bone Marrow Transplant Date: 2000-01 Impact factor: 5.483
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191
Authors: Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova Journal: Haematologica Date: 2013-12 Impact factor: 9.941
Authors: Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson Journal: J Antimicrob Chemother Date: 2010-04-02 Impact factor: 5.790